Evidence map›Paper›PMID 36514248›Full record

ArticleInternational journal of geriatric psychiatry2023

Use of benzodiazepine and Z-drugs and mortality in older adults after myocardial infarction.

Shengxin Liu, Sabita S Soedamah-Muthu, Seia C van Meerten, Daan Kromhout, Johanna M Geleijnse, Erik J Giltay

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of geriatric psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00127452 (Alpha Omega Trial), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00127452 nacompletednot on this map

Alpha Omega Trial: A Randomised, Placebo Controlled, Double Blind Intervention Study of the Effect of Low Doses of Omega-3 Fatty Acids on Cardiovascular Diseases in Patients With a History of Myocardial Infarction

TypeinterventionalSponsorWageningen UniversityRan2002 to 2010Enrolled4,837ConditionsCardiovascular DiseasesArmsmargarine spread
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shengxin LiuDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.
Sabita S Soedamah-MuthuCenter of Research on Psychological Disorders and Somatic Diseases (CoRPS), Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands.
Seia C van MeertenDepartment of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands.
Daan KromhoutDepartment of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Johanna M GeleijnseDivision of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands.
Erik J GiltayDepartment of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands.

Funding

Alpha Omega TrialR01HL076200 · NHLBI · WAGENINGEN UNIVERSITY · PI KROMHOUT, DAAN · 2005 to 2008
$1.9M
NHLBI NIH HHS R01 HL076200
6 · The paper itself

Abstract

backgroundThe adverse cardiovascular effects of benzodiazepines and Z-drugs (jointly referred as BZDRs) have been of concern. Yet, little is known about the use of BZDRs in relation to mortality risk among older adults with myocardial infarction history (post-MI).

methodsThis study is a secondary analysis of the Alpha Omega Cohort study, comprising post-MI patients aged 40-60 years. Self-reported information on the use of BZDRs, including types and dose, was collected at baseline. Four categories of mortality were examined, namely all-cause mortality, cardiovascular (CVD) mortality, cancer mortality, and non-CVD/non-cancer mortality. Associations between BZDRs use, by types and doses, and mortality were estimated with Cox regression models, adjusted for demographic and classic cardiovascular risk factors.

resultsA total of 433 (8.9%) out of 4837 (21.8% females) patients reported BZDRs use at baseline. During a median follow-up of 12.4 years, 2287 deaths were documented, of which 825 (36.1%) were due to CVD. BZDRs use was related to a statistically significantly higher risk of all-cause and CVD mortality; adjusted hazard ratios [95% CI] were (1.31 [1.41, 1.52]) and (1.43 [1.14, 1.81]), respectively. These relationships were dose-dependent-patients using BZDRs on an as-needed basis had similar risks compared to the non-uses, whereas patients with a daily use schedule and increasing doses had higher risks (p-value for trend: <0.001).

conclusionBZDRs use was independently associated with a higher risk of all-cause and cardiovascular mortality in older post-MI patients, and there was evidence for a dose-dependent relationship. CLINICAL

trial registrationNCT00127452 (www. CLINICALTRIALS: gov).

Indexed as

Cardiovascular DiseasesMyocardial InfarctionAgedBenzodiazepinesCohort StudiesFemaleHumansMaleProportional Hazards ModelsRisk FactorsBenzodiazepinesall-cause mortalitybenzodiazepinecardiovascular mortalitydose-dependent

Identifiers

PMID36514248
PMCPMC10107716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.